Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

BACKGROUND: Afatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of afatinib in EGFR tyrosine kinase inhibitor (TKI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Passaro, Antonio, de Marinis, Filippo, Tu, Hai-Yan, Laktionov, Konstantin K., Feng, Jifeng, Poltoratskiy, Artem, Zhao, Jun, Tan, Eng Huat, Gottfried, Maya, Lee, Victor, Kowalski, Dariusz, Yang, Cheng Ta, Srinivasa, BJ, Clementi, Laura, Jalikop, Tejaswini, Huang, Dennis Chin Lun, Cseh, Agnieszka, Park, Keunchil, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298067/
https://www.ncbi.nlm.nih.gov/pubmed/34307179
http://dx.doi.org/10.3389/fonc.2021.709877

Ejemplares similares

Ejemplares similares